# HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma

> **NCT07697339** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len
- **DRUG:** Rituximab plus lenalidomide
- **DRUG:** Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len
- **DRUG:** HDM2005 plus rituximab and lenalidomide

## Key facts

- **NCT ID:** NCT07697339
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2027-08-10
- **Final completion:** 2028-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697339, "HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*